Clinical Trial Update: Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

View source ↗

Summary

This study evaluated real-world effectiveness of palbociclib plus endocrine therapy as first- or second-line treatment for HR+/HER2- advanced breast cancer in J…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Status: COMPLETED